Cost-effectiveness of statins for primary prevention in patients newly diagnosed with type 2 diabetes in the Netherlands
BACKGROUND: Statins are lipid-lowering drugs that reduce the risk of cardiovascular events in patients with diabetes. OBJECTIVES: The objective of this study was to determine whether statin treatment for primary prevention in newly diagnosed type 2 diabetes is cost-effective, taking nonadherence, baseline risk, and age into account. METHODS: A cost-effectiveness analysis was performed by using a Markov model with a time horizon of 10 years. The baseline 10-year cardiovascular risk was estimated in a Dutch population of primary prevention patients with newly diagnosed diabetes from the Groninge... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2014 |
Reihe/Periodikum: | de Vries , F M , Denig , P , Visser , S T , Hak , E & Postma , M J 2014 , ' Cost-effectiveness of statins for primary prevention in patients newly diagnosed with type 2 diabetes in the Netherlands ' , Value in Health , vol. 17 , no. 2 , pp. 223-230 . https://doi.org/10.1016/j.jval.2013.12.010 |
Schlagwörter: | Adult / Age Factors / Aged / Cardiovascular Diseases / Cost-Benefit Analysis / Databases / Factual / Diabetes Mellitus / Type 2 / Female / Humans / Hydroxymethylglutaryl-CoA Reductase Inhibitors / Male / Markov Chains / Medication Adherence / Middle Aged / Netherlands / Primary Prevention / Quality-Adjusted Life Years / Risk Factors |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26825897 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://hdl.handle.net/11370/8d72c77d-4d04-4dc9-9953-38fa7bfd0fcb |
BACKGROUND: Statins are lipid-lowering drugs that reduce the risk of cardiovascular events in patients with diabetes. OBJECTIVES: The objective of this study was to determine whether statin treatment for primary prevention in newly diagnosed type 2 diabetes is cost-effective, taking nonadherence, baseline risk, and age into account. METHODS: A cost-effectiveness analysis was performed by using a Markov model with a time horizon of 10 years. The baseline 10-year cardiovascular risk was estimated in a Dutch population of primary prevention patients with newly diagnosed diabetes from the Groningen Initiative to Analyse Type 2 Diabetes Treatment (GIANTT) database, using the United Kingdom Prospective Diabetes Study risk engine. Statin adherence was measured as pill days covered in the IADB.nl pharmacy research database. Cost-effectiveness was measured in costs per quality-adjusted life-year (QALY) from the health care payers' perspective. RESULTS: For an average patient aged 60 years, the base case, statin treatment was highly cost-effective at €2245 per QALY. Favorable cost-effectiveness was robust in sensitivity analysis. Differences in age and 10-year cardiovascular risk showed large differences in cost-effectiveness from almost €100,000 per QALY to almost being cost saving. Treating all patients younger than 45 years at diabetes diagnosis was not cost-effective (weighted cost-effectiveness of almost €60,000 per QALY). CONCLUSIONS: Despite the nonadherence levels observed in actual practice, statin treatment is cost-effective for primary prevention in patients newly diagnosed with type 2 diabetes. Because of large differences in cost-effectiveness according to different risk and age groups, the efficiency of the treatment could be increased by targeting patients with relatively higher cardiovascular risk and higher ages.